JP2023546657A5 - - Google Patents
Info
- Publication number
- JP2023546657A5 JP2023546657A5 JP2023523033A JP2023523033A JP2023546657A5 JP 2023546657 A5 JP2023546657 A5 JP 2023546657A5 JP 2023523033 A JP2023523033 A JP 2023523033A JP 2023523033 A JP2023523033 A JP 2023523033A JP 2023546657 A5 JP2023546657 A5 JP 2023546657A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- cancer
- optionally
- patient
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063105773P | 2020-10-26 | 2020-10-26 | |
| US63/105,773 | 2020-10-26 | ||
| US202063120319P | 2020-12-02 | 2020-12-02 | |
| US63/120,319 | 2020-12-02 | ||
| US202163242849P | 2021-09-10 | 2021-09-10 | |
| US63/242,849 | 2021-09-10 | ||
| PCT/US2021/056700 WO2022093855A1 (en) | 2020-10-26 | 2021-10-26 | Treatment of cancers with gm-csf antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023546657A JP2023546657A (ja) | 2023-11-07 |
| JP2023546657A5 true JP2023546657A5 (https=) | 2024-11-05 |
Family
ID=78820846
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023523033A Pending JP2023546657A (ja) | 2020-10-26 | 2021-10-26 | Ｇｍ－ｃｓｆ拮抗薬を用いたがんの治療 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220184179A1 (https=) |
| EP (1) | EP4232162A1 (https=) |
| JP (1) | JP2023546657A (https=) |
| KR (1) | KR20230095983A (https=) |
| AU (1) | AU2021372454A1 (https=) |
| WO (1) | WO2022093855A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240309079A1 (en) * | 2023-03-14 | 2024-09-19 | Taran Therapeutics, Inc. | Combination treatment of chronic myelomonocytic leukemia in patients with ras pathway mutations |
| WO2025096692A2 (en) * | 2023-11-01 | 2025-05-08 | Taran Therapeutics, Inc. | Combination treatment of chronic myelomonocytic leukemia in patients with ras pathway mutations |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| RU2447085C2 (ru) | 2005-05-18 | 2012-04-10 | МорфоСис АГ | Анти-gm-csf антитела и их применение |
| JP4943044B2 (ja) | 2005-07-20 | 2012-05-30 | リンテック株式会社 | 粘着シート |
| MX2008012291A (es) | 2006-03-27 | 2009-01-12 | Medimmune Ltd | Miembro que enlaza al receptor gm-csf. |
| CN103827143A (zh) * | 2011-07-06 | 2014-05-28 | 莫弗系统股份公司 | 抗cd20抗体和抗gm-csf抗体的治疗性组合产品及其用途 |
| WO2013026059A1 (en) * | 2011-08-18 | 2013-02-21 | New York University | Inhibition of oncogenic kras-induced gm-csf production and function |
| CA2851322C (en) | 2011-10-10 | 2020-03-31 | Medimmune Limited | Treatment for rheumatoid arthritis with gm csfr alpha antibodies |
| CN106456761A (zh) | 2014-05-19 | 2017-02-22 | 免疫医疗有限公司 | 对类风湿关节炎的治疗 |
| EP3786293A1 (en) | 2015-06-12 | 2021-03-03 | AxioMx, Inc. | Methods and compositions for producing a chimeric polypeptide |
| GB201519331D0 (en) * | 2015-11-02 | 2015-12-16 | Glaxosmithkline Ip Dev Ltd | Treatment paradigm |
| AU2018345751A1 (en) * | 2017-10-02 | 2020-05-07 | Humanigen, Inc. | Methods of treating immunotherapy-related toxicity using a GM-CSF antagonist |
| CN109120869B (zh) * | 2018-11-07 | 2024-09-06 | 深圳市道通智能航空技术股份有限公司 | 双光图像整合方法、整合设备及无人机 |
| AU2019377515A1 (en) * | 2018-11-09 | 2021-05-27 | Kiniksa Pharmaceuticals, Gmbh | Treatment for giant cell arteritis |
| US20220331425A1 (en) * | 2019-06-03 | 2022-10-20 | Kiniksa Pharmaceuticals, Ltd. | Treatment of cancers with gm-csf antagonists |
-
2021
- 2021-10-26 WO PCT/US2021/056700 patent/WO2022093855A1/en not_active Ceased
- 2021-10-26 US US17/511,183 patent/US20220184179A1/en not_active Abandoned
- 2021-10-26 JP JP2023523033A patent/JP2023546657A/ja active Pending
- 2021-10-26 EP EP21819269.8A patent/EP4232162A1/en active Pending
- 2021-10-26 AU AU2021372454A patent/AU2021372454A1/en not_active Abandoned
- 2021-10-26 KR KR1020237015960A patent/KR20230095983A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Meric-Bernstam et al. | Enhancing anti-tumour efficacy with immunotherapy combinations | |
| Liu et al. | Risk factors for immune-related adverse events: what have we learned and what lies ahead? | |
| Sehn et al. | Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after≥ 2 prior therapies | |
| Liu et al. | The BRAF and MEK inhibitors dabrafenib and trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4 | |
| Wang et al. | Decitabine enhances lymphocyte migration and function and synergizes with CTLA-4 blockade in a murine ovarian cancer model | |
| JP2022535062A5 (https=) | ||
| JP2020503273A5 (https=) | ||
| KR20150042784A (ko) | Ｃａｒ의 항-종양 활성에 대한 독성 관리 | |
| JP2022532490A5 (https=) | ||
| Eckmann et al. | Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+ 1 format, for the treatment of multiple myeloma | |
| JP2023546657A5 (https=) | ||
| US20250313855A1 (en) | Chimeric antigen receptor t cell therapy | |
| Duong et al. | T cell Immunoglobulin and mucin domain containing protein 3 (TIM-3) inhibitors in oncology clinical trials: a review | |
| CN113396230A (zh) | 癌症的诊断和治疗方法 | |
| US9772327B2 (en) | Initial relative lymphocyte count as predictive biomarker | |
| JP7274454B2 (ja) | チェックポイント阻害薬のための予測末梢血バイオマーカー | |
| TWI828626B (zh) | 併用包含溶血性鏈球菌之菌體的製劑的療法 | |
| Uy et al. | Prophylactic ruxolitinib for cytokine release syndrome (CRS) in relapse/refractory (R/R) AML patients treated with flotetuzumab | |
| Sweis et al. | A Phase II Open-Label, Randomized Clinical Trial of Atezolizumab with or without Human Recombinant IL-7 (CYT107) in Advanced Urothelial Cancer | |
| Grainger et al. | Doubling down: the new deal in the clinical management of double-refractory chronic lymphocytic leukemia | |
| Salkeni et al. | Resistance to immunotherapy: mechanisms and means for overcoming | |
| US20200385478A1 (en) | Compositions and methods for cancer immunotherapy | |
| Kudo-Saito et al. | Targeting myeloid villains in the treatment with immune checkpoint inhibitors in gastrointestinal cancer | |
| TW202304512A (zh) | 雙特異性t細胞銜接體之給藥 | |
| Kelley et al. | T-Cell Receptor and Immune Gene Expression Pharmacodynamics for Durvalumab Alone and with Tremelimumab or Bevacizumab in Unresectable Hepatocellular Carcinoma |